Vincenzo Faiola
Overview
Explore the profile of Vincenzo Faiola including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
283
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Addeo R, Sgambato A, Cennamo G, Montella L, Faiola V, Abbruzzese A, et al.
Clin Breast Cancer
. 2010 Aug;
10(4):301-6.
PMID: 20705563
Background: The concept of metronomic chronic administration of low-dose chemotherapy has become relevant for the treatment of cancer in the last several years. This study sought to determine the safety...
2.
Addeo R, Caraglia M, De Santi M, Montella L, Abbruzzese A, Parlato C, et al.
J Neurooncol
. 2010 Aug;
102(3):417-24.
PMID: 20694830
In the present study we investigated the feasibility and effectiveness of a new biweekly schedule of fotemustine (FTM) in patients with recurrent glioblastoma, after at least one previous treatment. The...
3.
Prete S, Montella L, Caraglia M, Maiorino L, Cennamo G, Montesarchio V, et al.
Cancer Chemother Pharmacol
. 2009 Dec;
66(5):837-44.
PMID: 20041325
Purpose: Advanced hepatocellular carcinoma (HCC) not eligible for local therapies has limited chances of cure. Sorafenib is a multikinase inhibitor with proven activity in advanced HCC. Octreotide is used in...
4.
Addeo R, Caraglia M, Bellini S, Abbruzzese A, Vincenzi B, Montella L, et al.
J Clin Oncol
. 2009 Oct;
28(4):543-8.
PMID: 19841330
Purpose: Approximately 30% to 40% patients with a superficial bladder cancer treated with Bacille Calmette-Guerin (BCG) or epirubicin do not respond; of the initial responders, 35% have a relapse within...
5.
Montella L, Addeo R, Palmieri G, Caraglia M, Cennamo G, Vincenzi B, et al.
Cancer Chemother Pharmacol
. 2009 Sep;
65(6):1137-43.
PMID: 19760218
Purpose: The survival of patients with hepatocellular carcinoma (HCC) has improved with advancements in various diagnostic tools and treatment modalities. Consequently, bone metastases from HCC are diagnosed more frequently. The...
6.
Montella L, Addeo R, Faiola V, Cennamo G, Guarrasi R, Capasso E, et al.
J Exp Clin Cancer Res
. 2009 Jan;
28:7.
PMID: 19144109
Introduction: Chondrosarcomas and chordomas are usually chemoresistant bone tumors and may have a poor prognosis when advanced. They are usually associated with worsening pain difficult to control. Patients And Methods:...
7.
Addeo R, De Rosa C, Faiola V, Leo L, Cennamo G, Montella L, et al.
Cancer
. 2008 Sep;
113(9):2524-31.
PMID: 18798231
Background: Temozolomide (TMZ), an oral methylating imidazotetrazinone, has antitumor activity against gliomas, malignant melanomas, and brain metastasis and is presently administered as a 5-day oral schedule every 4 weeks. Methods:...
8.
Addeo R, Montella L, Baldi A, Cennamo G, Guarrasi R, Faiola V, et al.
Clin Colorectal Cancer
. 2007 Nov;
6(10):728-30.
PMID: 18039427
Some conditions are predisposed to excessive lymphocyte responses, which can progress to a benign condition, ie, atypical cutaneous lymphoid hyperplasia (ACLH), or a malignant lymphoma. Clinical diagnosis of drug-associated pseudolymphoma...
9.
Addeo R, Faiola V, Guarrasi R, Montella L, Vincenzi B, Capasso E, et al.
Cancer Chemother Pharmacol
. 2007 Oct;
62(2):285-92.
PMID: 17922275
Purpose: No standard chemotherapy has been so far definitely settled for elderly patients with metastatic breast cancer (MBC). In order to identify a regimen with acceptable efficacy and low burden...
10.
Addeo R, Nocera V, Faiola V, Vincenzi B, Ferraro G, Montella L, et al.
Support Care Cancer
. 2007 Aug;
16(2):209-14.
PMID: 17701225
Goals Of Work: Bone metastases are a common cause of morbidity in elderly patients with solid tumors and myeloma. We studied the safety and the effect of a new bisphosphonate,...